Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Statistics in Medicine|January 31, 2007
A three-outcome design for randomized comparative phase II clinical trialsShengyan Hong, Yanping Wang
Statistics in Medicine|February 4, 2012
Predictive power to assist phase 3 go/no go decision based on phase 2 data on a different endpointShengyan Hong, Li Shi
Statistics in Medicine|September 2, 2008
The type I error and power of non-parametric logrank and Wilcoxon tests with adjustment for covariates--a simulation studyHonghua Jiang, James Symanowski, Sofia Paul, et al.
Journal of Neuro-Oncology|November 16, 2016
Phase II study of MEDI-575, an anti-platelet-derived growth factor-α antibody, in patients with recurrent glioblastomaSurasak Phuphanich, Jeffrey Raizer, Marc Chamberlain, et al.
Cancer Chemotherapy and Pharmacology|August 24, 2014
A phase I dose-escalation study of MEDI-575, a PDGFRα monoclonal antibody, in adults with advanced solid tumorsCarlos R Becerra, Paul Conkling, Nicholas Vogelzang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2008
Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesotheliomaJacek Jassem, Rodryg Ramlau, Armando Santoro, et al.
Clinical Colorectal Cancer|December 17, 2005
Phase I/II dose-escalation study of pemetrexed plus irinotecan in patients with advanced colorectal cancerHoward Hochster, Erika Kettner, Hendrik Kroning, et al.
Clinical Lung Cancer|July 28, 2009
Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancerJyoti D Patel, Philip Bonomi, Mark A Socinski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2007
A phase I and pharmacokinetic study of pemetrexed plus irinotecan in patients with advanced solid malignanciesEric K Rowinsky, Muralidhar Beeram, Lisa A Hammond, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 4, 2010
Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastomaWolfgang Wick, Vinay K Puduvalli, Marc C Chamberlain, et al.
Pageof 2